Published online before print October 6, 2005, doi: 10.1161/01.RES.0000189302.03303.11
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 American Heart Association, Inc.
Clinical Research |
Haplotype Effect of the Matrix Metalloproteinase-1 Gene on Risk of Myocardial Infarction
From the Human Genetics Division (E.P., A.R.M., C.C., S.Y.), School of Medicine, University of Southampton, United Kingdom; INSERM U525 (D.-A.T), Faculté de Médecine, Hôpital Pitié-Salpêtrière, Paris, France; and Atherosclerosis Research Unit (A.S., A.H., P.E.), King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden.
Correspondence to Dr Shu Ye, Human Genetics Division, School of Medicine, University of Southampton, Southampton General Hospital, Duthie Bldg (Mp 808), Tremona Rd, Southampton SO16 6YD, United Kingdom. E-mail Shu.Ye{at}soton.ac.uk
Myocardial infarction (MI) is commonly caused by atherosclerotic plaque rupture following excessive degradation of collagen fibers in the atherosclerotic lesion. We investigated whether interindividual variability in risk of MI was related to polymorphisms in the gene encoding matrix metalloproteinase (MMP)-1, a key fibrillar collagen–degrading enzyme. Several single nucleotide polymorphisms in the MMP1 gene promoter were identified following sequencing DNA samples from 30 individuals. An analysis of the polymorphisms in a cohort of British whites with coronary atherosclerosis, including 639 patients with MI and 538 non-MI subjects, revealed a haplotype effect of the –519A>G and –340T>C polymorphisms on risk of MI, with the A–519-C–340 and G–519-T–340 haplotypes being protective (odds ratio=0.70 [0.57 to 0.86]; P=0.0007), whereas the G–519-C–340 haplotype increased MI risk (odds ratio=1.94 [1.15 to 3.28]; P=0.013). This finding was replicated in a subsequent analysis of 387 Swedish MI patients and 387 healthy controls (odds ratio=0.70 [0.55 to 0.89], P=0.003, for A–519-C–340 and G–519-T–340; odds ratio=1.54 [0.97 to 2.46], P=0.07, for G–519-C–340). In vitro assays showed that compared with the A–519-T–340 haplotype, the A–519-C–340 and G–519-T–340 haplotypes had lower promoter activity, whereas the G–519-C–340 haplotype had greater promoter strength, in driving gene expression in human macrophages. Haplotype-specific differences in MMP1 mRNA level in atherosclerotic tissues were also detected. The data indicate that MMP1 gene variation is a genetic factor contributing to interindividual differences in MI risk.
Key Words: matrix metalloproteinase • genetics • polymorphism • haplotype analysis • atherosclerosis
Related Article:
Circ. Res. 2005 97: 958-960.
This article has been cited by other articles:
 |
|
 |
|
  Z. Mallat Matrix Metalloproteinase-8 and the Regulation of Blood Pressure, Vascular Inflammation, and Atherosclerotic Lesion Growth Circ. Res., October 23, 2009; 105(9): 827 - 829. [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. Cheng, W.-H. L. Kao, B. D. Mitchell, J. R. O'Connell, H. Shen, P. F. McArdle, Q. Gibson, K. A. Ryan, A. R. Shuldiner, and T. I. Pollin Genome-Wide Association Scan Identifies Variants near Matrix Metalloproteinase (MMP) Genes on Chromosome 11q21-22 Strongly Associated With Serum MMP-1 Levels Circ Cardiovasc Genet, August 1, 2009; 2(4): 329 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cozzolino, M. L. Biondi, A. Galassi, O. Turri, D. Brancaccio, and M. Gallieni Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with mortality in haemodialysis patients Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2207 - 2212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yoshida, K. Kato, T. Fujimaki, K. Yokoi, M. Oguri, S. Watanabe, N. Metoki, H. Yoshida, K. Satoh, Y. Aoyagi, et al. Association of Genetic Variants with Chronic Kidney Disease in Japanese Individuals Clin. J. Am. Soc. Nephrol., May 1, 2009; 4(5): 883 - 890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Hodgkinson, R. C. Laxton, K. Patel, and S. Ye Advanced Glycation End-Product of Low Density Lipoprotein Activates the Toll-Like 4 Receptor Pathway Implications for Diabetic Atherosclerosis Arterioscler Thromb Vasc Biol, December 1, 2008; 28(12): 2275 - 2281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Armstrong, S. Abilleira, M. Sitzer, H. S. Markus, and S. Bevan Polymorphisms in MMP Family and TIMP Genes and Carotid Artery Intima-Media Thickness Stroke, November 1, 2007; 38(11): 2895 - 2899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.E. Morange, N. Saut, M.C. Alessi, J.S. Yudkin, M. Margaglione, G. Di Minno, A. Hamsten, S.E. Humphries, D.A. Tregouet, and I. Juhan-Vague Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters: The HIFMECH Study Arterioscler Thromb Vasc Biol, October 1, 2007; 27(10): 2250 - 2257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Pearce, R. C. Laxton, A. C. Pereira, and S. Ye Haplotype Effects on Matrix Metalloproteinase-1 Gene Promoter Activity in Cancer Cells Mol. Cancer Res., March 1, 2007; 5(3): 221 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Newby and J. L. Johnson Genetic Strategies to Elucidate the Roles of Matrix Metalloproteinases in Atherosclerotic Plaque Growth and Stability Circ. Res., November 11, 2005; 97(10): 958 - 960. [Full Text] [PDF]
|
|